Archive for the 'Zengen, Inc.' Category

Zengen, Inc. news feed.

Zengen’s new study reviews novel approach to control inflammation using melanocortin receptors; Study supports development potential in several therapeutic areas

WOODLAND HILLS, Calif. Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders. The findings, "Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation," appear in the March 2004 issue of Pharmacological Reviews, a publication of


Last update: April 01, 2019. 03:30:08 pm.